

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Jo Klaveness et al.
Application No. : 10/573,606
Filing Date : March 28, 2006
Art Unit : 6864
Title : Optical Imaging of Colorectal Cancer
Docket No. : PN0368

Mail Stop Appeal Brief – Patents
Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

SUBSTITUTE APPEAL BRIEF IN RESPONSE TO A
NON-COMPLIANT NOTIFICATION

Madam:

This is in response to a Notification of Non-Compliant Appeal Brief (“Notification”) mailed March 4, 2008.

Per the Notification, Appellants respectfully submit only a complete and newly amended section V in response to the Notification for reasons set forth under 37 CFR 41.37 (c)(1)(v).

V. SUMMARY OF CLAIMED SUBJECT MATTER

Independent Claim 13 describes an optical imaging contrast agent with affinity for an abnormally expressed biological target associated with colorectal cancer (CRC). The contrast agent is of formula I:



wherein:

V is one or more vector moieties having affinity for an abnormally expressed target in CRC, where said target is selected from c-met, MMP-14, COX-2, beta-catenin and cathepsin B;

L is a linker moiety or a bond, and

R is one or more reporter moieties detectable in optical imaging, wherein the contrast agent has a molecular weight below 10,000 Daltons.

Support for claim 13 can be found on page 7, lines 10-30 of the specification.

Dated: March 11, 2008

Respectfully submitted,

/Craig M. Bohlken/
Craig M. Bohlken
Reg. No. 52,628
GE Healthcare, Inc.
101 Carnegie Center
Princeton, NJ 08540-6231
Phone No.: (609) 514-6530